Pulmonx Corp (NASDAQ: LUNG) closed the day trading at $9.36 down -7.51% from the previous closing price of $10.12. In other words, the price has decreased by -$0.76 from its previous closing price. On the day, 1559241 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a better understanding of LUNG, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.77 and its Current Ratio is at 6.49. In the meantime, Its Debt-to-Equity ratio is 0.35 whereas as Long-Term Debt/Eq ratio is at 0.31.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on February 23, 2024, Downgraded its rating to Equal Weight and sets its target price to $14 from $16 previously.
On September 05, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $18.
Wells Fargo Upgraded its Equal Weight to Overweight on February 27, 2023, whereas the target price for the stock was revised from $10 to $15.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 22 when Rose Geoffrey Beran sold 1,184 shares for $14.20 per share. The transaction valued at 16,813 led to the insider holds 243,049 shares of the business.
French Glendon E. III sold 20,000 shares of LUNG for $292,000 on Feb 15. The PRESIDENT AND CEO now owns 1,121,344 shares after completing the transaction at $14.60 per share. On Jan 22, another insider, Rose Geoffrey Beran, who serves as the CHIEF COMMERCIAL OFFICER of the company, sold 1,184 shares for $13.13 each. As a result, the insider received 15,546 and left with 244,233 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LUNG now has a Market Capitalization of 387.68M and an Enterprise Value of 312.00M. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.22 while its Price-to-Book (P/B) ratio in mrq is 3.05. Its current Enterprise Value per Revenue stands at 4.54 whereas that against EBITDA is -5.47.
Stock Price History:
Over the past 52 weeks, LUNG has reached a high of $14.84, while it has fallen to a 52-week low of $7.75. The 50-Day Moving Average of the stock is 13.10, while the 200-Day Moving Average is calculated to be 11.71.
Shares Statistics:
Over the past 3-months, LUNG traded about 357.25K shares per day on average, while over the past 10 days, LUNG traded about 740.6k shares per day. A total of 38.52M shares are outstanding, with a floating share count of 35.08M. Insiders hold about 8.44% of the company’s shares, while institutions hold 88.47% stake in the company. Shares short for LUNG as of Feb 15, 2024 were 1.26M with a Short Ratio of 3.53, compared to 1.56M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.29% and a Short% of Float of 4.02%.
Earnings Estimates
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of -$0.46 for the current quarter, with a high estimate of -$0.4 and a low estimate of -$0.5, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.39 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$1.54 and -$1.94 for the fiscal current year, implying an average EPS of -$1.8. EPS for the following year is -$1.51, with 6 analysts recommending between -$1.17 and -$1.81.
Revenue Estimates
6 analysts predict $17.74M in revenue for the current quarter. It ranges from a high estimate of $18.8M to a low estimate of $17M. As of the current estimate, Pulmonx Corp’s year-ago sales were $13.49M, an estimated increase of 31.50% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $20.38M, an increase of 18.50% less than the figure of $31.50% in the same quarter last year. There is a high estimate of $20.75M for the next quarter, whereas the lowest estimate is $19.4M.
A total of 6 analysts have provided revenue estimates for LUNG’s current fiscal year. The highest revenue estimate was $82.9M, while the lowest revenue estimate was $77.4M, resulting in an average revenue estimate of $81.39M. In the same quarter a year ago, actual revenue was $68.67M, up 18.50% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $97.14M in the next fiscal year. The high estimate is $101.1M and the low estimate is $92.8M. The average revenue growth estimate for next year is up 19.40% from the average revenue estimate for this year.
